Stock Monitor: Madrigal Pharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on Therapix Biosciences Ltd (NASDAQ: TRPX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=TRPX as the Company's latest news hit the wire. On April 09, 2018, the Company announced positive top-line results from its investigator-initiated Phase-IIa study at Yale University, for treatment of Tourette syndrome. The results suggested that THX-110 [which is a combination of dronabinol (-9-tetrahydracannabinol) and palmitoylethanolamide (PEA)] significantly improved symptoms over time in adult subjects with Tourette syndrome. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), which also belongs to the Healthcare sector as the Company Therapix Biosciences. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Therapix Biosciences most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Primary Endpoint was to Assess the Performance of THX-110 in Treatment of Adult Patients Suffering from Tourette Syndrome
The Phase-IIa study was a single-arm, open-label trial, which enrolled 16 subjects and each subject both received one daily treatment of THX-110 via oral administration and was followed-up for a period of 12 weeks. The primary endpoint of the study was to assess the performance of THX-110 in the treatment of adult patients suffering from symptoms of Tourette syndrome, as measured by the Yale Global Tic Severity Scale Total Tic Score (YGTSS-TTS), the gold-standard and customary index for assessing symptom severity. Treatment was given in a dose titration regimen with a maximum dose of THX-110 consisting of 10mg Dronabinol and 800mg PEA.
Subset of the Subjects Experienced Improvement in Tic Symptoms
The study showed that these 16 subjects with medication-refractory TS had a reduction of tic symptoms, resulting in an average tic reduction of 21% across the entire sample. Six of the 16 medication-refractory TS subjects experienced a response to treatment as defined by a reduction in YGTSS-TTS of greater than 25%. Improvement over time with treatment was also observed when generalized linear models were used to analyze repeated measures data on the YGTSS-TTS. THX-110 demonstrated no significant effects on comorbidity. The medication was generally well-tolerated by subjects. Twelve of the 16 subjects elected to continue into a 24-week extension phase of the trial, which is nearing completion.
Complete results from this study will be presented at the 2018 European Society for the Study of Tourette syndrome meeting in Copenhagen, Denmark.
Therapix to Initiate a Study to Evaluate the Safety and Efficacy of Daily Oral THX-110 in Treating Tourette Syndrome
Adi Zuloff-Shani, Ph. D, Chief Technology Officer at Therapix, said that these results are of particular interest as the pharmacology of THX-110 appears to be distinct from existing medications for TS and may offer a unique option for treating these patients. This study was designed primarily to confirm safety, tolerability and feasibility in this challenging patient population and is encouraging that we obtained positive data that suggests that the combination of dronabinol (-9-tetrahydracannabinol) and palmitoylethanolamide (PEA) (THX-110) should be pursued as a treatment for TS patients.
Dr. Adi added that based on these study results, the Company intends to initiate a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of daily oral THX-110 in treating adults with Tourette syndrome.
News report suggests that post the announcement of the news, shares of Therapix surged in pre-market trade.
Therapix Completed Pre-IND Communication with FDA on THX-110 for Tourette Syndrome
On February 07, 2018, Therapix held a pre-Investigational New Drug (pre-IND) communication with the US Food and Drug Administration (FDA) to discuss the regulatory pathway for the development of THX-110 for the treatment of Tourette Syndrome. Following the communication, the Company confirmed that the IND for THX-110 would not require any additional nonclinical data to support a phase-IIb study in the United States. Therapix intends to submit a NDA via the 505(b)(2) pathway.
About Tourette Syndrome
Tourette syndrome (TS) is a common neuropsychiatric disorder with onset in childhood, characterized by multiple motor tics and at least one vocal (phonic) tic. These tics characteristically wax and wane, can be suppressed temporarily, and are typically preceded by an unwanted urge or sensation in the affected muscles. Some common tics are eye blinking, coughing, throat clearing, sniffing, and facial movements. Tourette's does not adversely affect intelligence or life expectancy.
About Therapix Biosciences Ltd
Founded in 2004 and headquartered in Tel Aviv, Israel, Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based therapies, proprietary formulation for the treatment of CNS and pain disorders.
Stock Performance Snapshot
April 10, 2018 - At Tuesday's closing bell, Therapix Biosciences' stock tumbled 11.31%, ending the trading session at $5.33.
Volume traded for the day: 227.08 thousand shares, which was above the 3-month average volume of 122.42 thousand shares.
After yesterday's close, Therapix Biosciences' market cap was at $218.52 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.8% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.